iRGD-guided tamoxifen polymersomes inhibit estrogen receptor transcriptional activity and decrease the number of breast cancer cells with self-renewing capacity

BACKGROUND: Tamoxifen (Tam) is the most frequent treatment for estrogen receptor (ER) positive breast cancer. We recently showed that fibronectin (FN) leads to Tam resistance and selection of breast cancer stem cells. With the aim of developing a nanoformulation that would simultaneously tackle ER a...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz Bessone, María Inés, Simón-Gracia, Lorena, Scodeller, Pablo, Ramirez, María de los Angeles, Lago Huvelle, María Amparo, Soler-Illia, Galo J. A. A., Simian, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898937/
https://www.ncbi.nlm.nih.gov/pubmed/31812165
http://dx.doi.org/10.1186/s12951-019-0553-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898937/
https://www.ncbi.nlm.nih.gov/pubmed/31812165
http://dx.doi.org/10.1186/s12951-019-0553-4

Ejemplares similares